Clivi aims to become the Livongo of Latin America for diabetes management

Date:

Mexico-based diabetes management startup, Clivi, has secured $10 million in seed funding to help tackle diabetes in Latin America, where there are more than 40 million adults with the condition. Clivi aims to offer a personalised, comprehensive and technological approach to diabetes healthcare delivery, with a focus on connecting patients with endocrinologists, nutritionists and psychologists and enabling users to access monitoring and treatment plans via their communication channel of choice, such as WhatsApp. The company also provides all necessary supplies and medication, and offers health plans starting from $40 per month. Clivi’s digital clinic and diabetes remote monitoring service has already helped thousands of patients, with 94% achieving diabetes control within six months of joining the platform.

See also  America's Unhealthy Relationship With Work Exposed by Tech Layoffs

Frequently Asked Questions (FAQs) Related to the Above News

What is Clivi?

Clivi is a Mexico-based diabetes management startup that offers a personalised, comprehensive and technological approach to diabetes healthcare delivery.

What is the goal of Clivi?

The goal of Clivi is to tackle the issue of diabetes in Latin America, where there are more than 40 million adults with the condition.

What services does Clivi offer?

Clivi offers a range of services, including connecting patients with endocrinologists, nutritionists and psychologists and enabling users to access monitoring and treatment plans via their communication channel of choice, such as WhatsApp. The company also provides all necessary supplies and medication and offers health plans starting from $40 per month.

How successful has Clivi been so far?

Clivi's digital clinic and diabetes remote monitoring service has already helped thousands of patients, with 94% achieving diabetes control within six months of joining the platform.

How much funding has Clivi secured?

Clivi has secured $10 million in seed funding to help further its mission of tackling diabetes in Latin America.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Advait Gupta
Advait Gupta
Advait is our expert writer and manager for the Artificial Intelligence category. His passion for AI research and its advancements drives him to deliver in-depth articles that explore the frontiers of this rapidly evolving field. Advait's articles delve into the latest breakthroughs, trends, and ethical considerations, keeping readers at the forefront of AI knowledge.

Share post:

Subscribe

Popular

More like this
Related

Obama’s Techno-Optimism Shifts as Democrats Navigate Changing Tech Landscape

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.